<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250206011539&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250206011539&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 06 Feb 2025 06:15:40 +0000</lastbuilddate>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Amara Yad Image: Cardiac Fibrous Skeleton</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909685/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):560-561. doi: 10.1016/j.jacc.2024.12.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909685/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909685</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.023>10.1016/j.jacc.2024.12.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909685</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: Cardiac Fibrous Skeleton</dc:title>
<dc:identifier>pmid:39909685</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.023</dc:identifier>
</item>
<item>
<title>Altering Adverse Social Determinants of Cardiovascular Health in Sexual Minorities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):526-527. doi: 10.1016/j.jacc.2024.12.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909684/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909684</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.012>10.1016/j.jacc.2024.12.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909684</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Caroline Ong</dc:creator>
<dc:creator>Billy A Caceres</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Altering Adverse Social Determinants of Cardiovascular Health in Sexual Minorities</dc:title>
<dc:identifier>pmid:39909684</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.012</dc:identifier>
</item>
<item>
<title>Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: An unfavorable SDOH profile was associated with worse CVH scores and higher cardiovascular mortality risk among SM individuals in the United States compared to their heterosexual counterparts.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):515-525. doi: 10.1016/j.jacc.2024.11.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite recent efforts to address health disparities regarding social determinants of health (SDOH), the intersection between SDOH and cardiovascular health (CVH) outcomes in sexual minority (SM) individuals remain largely underexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate associations between SDOH profile and CVH and mortality outcomes among SM individuals in the United States.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All participants aged ≥18 years surveyed in the 2013 to 2017 National Health Interview Survey were included, except those with missing data on SM status, any CVH or SDOH domain, or any other covariate. SM status was self-reported and categorized as lesbian/gay, bisexual, or uncertain. Participants' SDOH profile was quantified using a 6-domain (economic stability, neighborhood/physical environment/social cohesion, community and social context, food, education, and health care system), 38-item score, with higher scores indicating greater social deprivation. CVH was adapted from the American Heart Association's Life's Essential 8 framework. Because detailed dietary data were unavailable, a 7-item (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical inactivity, inadequate sleep, and obesity) CVH score was used, with higher scores indicating worse CVH. Additionally, cardiovascular mortality was ascertained through the National Death Index using death certificate information.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study sample consisted of 57,182 participants, representing a population of 82,826,690 persons. A worse composite SDOH score was associated with a worse CVH score in both heterosexual (adjusted rate ratio: 1.14; 95% CI: 1.13-1.15; P &lt; 0.001) and SM individuals (adjusted rate ratio: 1.16; 95% CI: 1.12-1.20; P &lt; 0.001), with associations appearing to be potentially stronger in the latter (P<sub>interaction</sub> = 0.042). Subgroup analysis demonstrated consistent associations among gay/lesbian individuals and bisexual individuals, but not in those with other or uncertain sexual orientations. Further exploratory analysis showed that a worse composite SDOH score was significantly associated with higher risk of cardiovascular mortality in both heterosexual (adjusted HR: 1.17; 95% CI: 1.06-1.28; P = 0.002) and SM individuals (adjusted HR: 2.25; 95% CI: 1.24-4.08; P = 0.008), with associations being significantly stronger in the latter (P interaction = 0.006).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An unfavorable SDOH profile was associated with worse CVH scores and higher cardiovascular mortality risk among SM individuals in the United States compared to their heterosexual counterparts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909683</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.026>10.1016/j.jacc.2024.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909683</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Danish Iltaf Satti</dc:creator>
<dc:creator>Jeffrey Shi Kai Chan</dc:creator>
<dc:creator>Reed Mszar</dc:creator>
<dc:creator>Adhya Mehta</dc:creator>
<dc:creator>Yaa Adoma Kwapong</dc:creator>
<dc:creator>Raymond Ngai Chiu Chan</dc:creator>
<dc:creator>Olayinka Agboola</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Jared A Spitz</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Zulqarnain Javed</dc:creator>
<dc:creator>Jason A Bonomo</dc:creator>
<dc:creator>Garima Sharma</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States</dc:title>
<dc:identifier>pmid:39909683</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.026</dc:identifier>
</item>
<item>
<title>Evolocumab in Older Individuals: Expanding the Age Horizon</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):513-514. doi: 10.1016/j.jacc.2024.11.043.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909682</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.043>10.1016/j.jacc.2024.11.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909682</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyani Dhar</dc:creator>
<dc:creator>Jeffrey Berger</dc:creator>
<dc:creator>Jonathan Newman</dc:creator>
<dc:creator>Arthur Schwartzbard</dc:creator>
<dc:creator>Astrid Carolina Jara Pernia</dc:creator>
<dc:creator>Howard S Weintraub</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evolocumab in Older Individuals: Expanding the Age Horizon</dc:title>
<dc:identifier>pmid:39909682</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.043</dc:identifier>
</item>
<item>
<title>Long-Term Lipid Lowering With Evolocumab in Older Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Early initiation of long-term evolocumab provides older patients with atherosclerotic cardiovascular disease cardiovascular benefits at least as good as those observed in younger patients, with a more favorable number needed to treat in older patients for reducing a composite endpoint and no significant safety concerns. These findings may be helpful in guiding future recommendations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):504-512. doi: 10.1016/j.jacc.2024.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Concerns about the efficacy and safety of intensive low-density lipoprotein cholesterol lowering in older patients have led to weaker recommendations in the U.S. guidelines for patients ≥75 years of age compared to younger patients. Data are sparse on long-term benefits of proprotein convertase subtilisin/kexin type 9 inhibition in older patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to assess the long-term benefit of evolocumab among patients aged ≥75 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial randomized 27,564 patients who were 18 to 85 years of age with atherosclerotic cardiovascular disease to evolocumab vs placebo with 2.2 years of median follow-up. In the open-label extension (FOURIER-OLE), 6,635 participants were transitioned to open-label evolocumab for an additional 5-year median follow-up. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was compared based on the original allocation to evolocumab vs placebo stratified by age (&lt;75 vs ≥75 years). Analyses were underpowered for individual components of the composite endpoint. The annualized incidence rates for adverse events of interest were calculated for the OLE population across age groups during the parent FOURIER trial by randomized treatment arm and during the combined parent and FOURIER-OLE studies for patients originally allocated to evolocumab.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 27,564 patients, 2,526 (9%) were ≥75 years of age at entry into FOURIER (median age: 77 years [Q1-Q3: 76-79 years]). The median follow-up in FOURIER and FOURIER-OLE was 7.1 years (Q1-Q3: 6.7-7.6 years), with a maximum of 8.7 years. Earlier initiation of evolocumab reduced the rate of the primary endpoint at least as well in older (HR: 0.79; 95% CI: 0.64-0.97) as in younger patients (HR: 0.86; 95% CI: 0.80-0.92; P interaction = 0.43). The absolute risk reductions were 5.4% (95% CI: -2.0% to 12.8%) in older and 2.3% (95% CI: 0.1%-4.5%) in younger patients, leading to numbers needed to treat of 19 and 44, respectively. The annualized incidence rates of safety events generally appeared similar across treatment arms in both age groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Early initiation of long-term evolocumab provides older patients with atherosclerotic cardiovascular disease cardiovascular benefits at least as good as those observed in younger patients, with a more favorable number needed to treat in older patients for reducing a composite endpoint and no significant safety concerns. These findings may be helpful in guiding future recommendations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909681</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.019>10.1016/j.jacc.2024.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909681</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Samer Al Said</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Xinhui Ran</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Anthony Keech</dc:creator>
<dc:creator>Jose H Flores-Arredondo</dc:creator>
<dc:creator>Bei Wang</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Lipid Lowering With Evolocumab in Older Individuals</dc:title>
<dc:identifier>pmid:39909681</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.019</dc:identifier>
</item>
<item>
<title>Does the Mechanism of Weight Loss Matter for Cardiovascular Protection?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):501-503. doi: 10.1016/j.jacc.2024.12.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909680</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.020>10.1016/j.jacc.2024.12.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909680</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Peder Langeland Myhre</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Does the Mechanism of Weight Loss Matter for Cardiovascular Protection?</dc:title>
<dc:identifier>pmid:39909680</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.020</dc:identifier>
</item>
<item>
<title>Making Secondary Prevention the Primary Focus for Cardiovascular Disease Control</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):451-453. doi: 10.1016/j.jacc.2024.11.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909679</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.040>10.1016/j.jacc.2024.11.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909679</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Oyere K Onuma</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Making Secondary Prevention the Primary Focus for Cardiovascular Disease Control</dc:title>
<dc:identifier>pmid:39909679</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.040</dc:identifier>
</item>
<item>
<title>PURE Evidence in Plain Sight: The Highs, Lows, and Gaps in Secondary Cardiovascular Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):448-450. doi: 10.1016/j.jacc.2024.11.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909678</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.034>10.1016/j.jacc.2024.11.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909678</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Abhishek Chaturvedi</dc:creator>
<dc:creator>Dorairaj Prabhakaran</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>PURE Evidence in Plain Sight: The Highs, Lows, and Gaps in Secondary Cardiovascular Prevention</dc:title>
<dc:identifier>pmid:39909678</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.034</dc:identifier>
</item>
<item>
<title>Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):436-447. doi: 10.1016/j.jacc.2024.10.121.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unclear whether global use of medications for secondary cardiovascular (CVD) prevention is improving over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study across 17 high-, middle- and low-income countries described variations in secondary CVD prevention medication use over a median follow-up of 12 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the multinational PURE (Prospective Urban Rural Epidemiology) cohort study, we conducted a repeated cross-sectional analysis to examine temporal variations in the use of secondary prevention medications in participants with CVD. In participants with coronary artery disease, we focused on antiplatelet agents, statins, renin-angiotensin system (RAS) inhibitors, and β-blockers. In participants with stroke, we focused on antiplatelet agents, statins, RAS inhibitors, and other blood pressure-lowering drugs. Medications were collected at baseline and on 4 subsequent follow-up visits.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 7,409 participants with a diagnosis of CVD at the baseline visit, 8,792 at the second visit, 9,236 at the third visit, 11,082 at the fourth visit, and 11,677 at the last visit. The median age at baseline was 58.0 years, and 52.9% of the participants were female. The median follow-up was 12 years, with the median year of the baseline visit in 2007 and the fifth visit in 2019. Over this period, use of 1 or more classes of medications for secondary CVD prevention was 41.3% (95% CI: 40.2%-42.4%) at baseline, peaked at 43.1% (95% CI: 42.0%-44.1%), and then decreased to 31.3% (95% CI: 30.4%-32.1%) by the last study visit. In high-income countries, this use decreased from 88.8% (95% CI: 86.6%-91.0%) to 77.3% (95% CI: 74.9%-79.6%). In upper-middle-income countries, this use increased from 55.0% (95% CI: 52.8%-57.3%) to 61.1% (95% CI: 59.1%-63.1%). In lower-middle-income countries, use of at least 1 class of medications was 29.5% (95% CI: 28.1%-30.9%) at baseline, peaked at 31.7% (95% CI: 30.4%-33.1%), and then decreased to 13.4% (95% CI: 12.5%-14.2%) by the last visit. In low-income countries, use of at least 1 class of medications was 20.8% (95% CI: 18.1%-23.5%) at baseline, peaked at 47.3% (95% CI: 44.8%-49.9%), and then decreased to 27.5% (95% CI: 25.2%-29.9%) by the last study visit.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909677</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.121>10.1016/j.jacc.2024.10.121</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909677</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Philip Joseph</dc:creator>
<dc:creator>Álvaro Avezum</dc:creator>
<dc:creator>Chinthanie Ramasundarahettige</dc:creator>
<dc:creator>Prem K Mony</dc:creator>
<dc:creator>Rita Yusuf</dc:creator>
<dc:creator>Khawar Kazmi</dc:creator>
<dc:creator>Andrzej Szuba</dc:creator>
<dc:creator>Patricio Lopez-Jaramillo</dc:creator>
<dc:creator>Maria Luz Diaz</dc:creator>
<dc:creator>Afzal Hussein Yusufali</dc:creator>
<dc:creator>Sadi Gulec</dc:creator>
<dc:creator>Roya Kelishadi</dc:creator>
<dc:creator>Li Wei</dc:creator>
<dc:creator>Jephat Chifamba</dc:creator>
<dc:creator>Fernando Lanas</dc:creator>
<dc:creator>Thandi Puoane</dc:creator>
<dc:creator>Ambigga Krishnapillai</dc:creator>
<dc:creator>Sumathy Rangarajan</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>PURE Investigators</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study</dc:title>
<dc:identifier>pmid:39909677</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.121</dc:identifier>
</item>
<item>
<title>Advancing Prevention: Insights From JACC's Focus Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):433-435. doi: 10.1016/j.jacc.2024.12.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909676</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.024>10.1016/j.jacc.2024.12.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909676</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advancing Prevention: Insights From JACC's Focus Issue</dc:title>
<dc:identifier>pmid:39909676</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.024</dc:identifier>
</item>
<item>
<title>ERC-funded Advanced Grant: creating molecular polypills</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909495/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehae866. doi: 10.1093/eurheartj/ehae866. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909495/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909495</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae866>10.1093/eurheartj/ehae866</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909495</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Georgios Krilis</dc:creator>
<dc:creator>Abdelaziz Beqqali</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>ERC-funded Advanced Grant: creating molecular polypills</dc:title>
<dc:identifier>pmid:39909495</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae866</dc:identifier>
</item>
<item>
<title>Rhodoquinone carries electrons in the mammalian electron transport chain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909039/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>Ubiquinone (UQ), the only known electron carrier in the mammalian electron transport chain (ETC), preferentially delivers electrons to the terminal electron acceptor oxygen (O(2)). In hypoxia, ubiquinol (UQH(2)) diverts these electrons onto fumarate instead. Here, we identify rhodoquinone (RQ), an electron carrier detected in mitochondria purified from certain mouse and human tissues that preferentially delivers electrons to fumarate through the reversal of succinate dehydrogenase, independent...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 10:S0092-8674(24)01420-X. doi: 10.1016/j.cell.2024.12.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ubiquinone (UQ), the only known electron carrier in the mammalian electron transport chain (ETC), preferentially delivers electrons to the terminal electron acceptor oxygen (O<sub>2</sub>). In hypoxia, ubiquinol (UQH<sub>2</sub>) diverts these electrons onto fumarate instead. Here, we identify rhodoquinone (RQ), an electron carrier detected in mitochondria purified from certain mouse and human tissues that preferentially delivers electrons to fumarate through the reversal of succinate dehydrogenase, independent of environmental O<sub>2</sub> levels. The RQ/fumarate ETC is strictly present in vivo and is undetectable in cultured mammalian cells. Using genetic and pharmacologic tools that reprogram the ETC from the UQ/O<sub>2</sub> to the RQ/fumarate pathway, we establish that these distinct ETCs support unique programs of mitochondrial function and that RQ confers protection upon hypoxia exposure in vitro and in vivo. Thus, in discovering the presence of RQ in mammals, we unveil a tractable therapeutic strategy that exploits flexibility in the ETC to ameliorate hypoxia-related conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39909039</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.007>10.1016/j.cell.2024.12.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909039</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan Valeros</dc:creator>
<dc:creator>Madison Jerome</dc:creator>
<dc:creator>Tenzin Tseyang</dc:creator>
<dc:creator>Paula Vo</dc:creator>
<dc:creator>Thang Do</dc:creator>
<dc:creator>Diana Fajardo Palomino</dc:creator>
<dc:creator>Nils Grotehans</dc:creator>
<dc:creator>Manisha Kunala</dc:creator>
<dc:creator>Alexandra E Jerrett</dc:creator>
<dc:creator>Nicolai R Hathiramani</dc:creator>
<dc:creator>Michael Mireku</dc:creator>
<dc:creator>Rayna Y Magesh</dc:creator>
<dc:creator>Batuhan Yenilmez</dc:creator>
<dc:creator>Paul C Rosen</dc:creator>
<dc:creator>Jessica L Mann</dc:creator>
<dc:creator>Jacob W Myers</dc:creator>
<dc:creator>Tenzin Kunchok</dc:creator>
<dc:creator>Tanner L Manning</dc:creator>
<dc:creator>Lily N Boercker</dc:creator>
<dc:creator>Paige E Carr</dc:creator>
<dc:creator>Muhammad Bin Munim</dc:creator>
<dc:creator>Caroline A Lewis</dc:creator>
<dc:creator>David M Sabatini</dc:creator>
<dc:creator>Mark Kelly</dc:creator>
<dc:creator>Jun Xie</dc:creator>
<dc:creator>Michael P Czech</dc:creator>
<dc:creator>Guangping Gao</dc:creator>
<dc:creator>Jennifer N Shepherd</dc:creator>
<dc:creator>Amy K Walker</dc:creator>
<dc:creator>Hahn Kim</dc:creator>
<dc:creator>Emma V Watson</dc:creator>
<dc:creator>Jessica B Spinelli</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Rhodoquinone carries electrons in the mammalian electron transport chain</dc:title>
<dc:identifier>pmid:39909039</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.007</dc:identifier>
</item>
<item>
<title>Sex-specific clinical course of young patients with Brugada syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 5:ehae739. doi: 10.1093/eurheartj/ehae739. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908976</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae739>10.1093/eurheartj/ehae739</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908976</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tomohiko Imamura</dc:creator>
<dc:creator>Takeru Makiyama</dc:creator>
<dc:creator>Junichi Ozawa</dc:creator>
<dc:creator>Keiko Sonoda</dc:creator>
<dc:creator>Koichi Kato</dc:creator>
<dc:creator>Takanori Aizawa</dc:creator>
<dc:creator>Asami Kashiwa</dc:creator>
<dc:creator>Jingshan Gao</dc:creator>
<dc:creator>Hai Huang</dc:creator>
<dc:creator>Yuta Yamamoto</dc:creator>
<dc:creator>Hirohiko Kohjitani</dc:creator>
<dc:creator>Hisaaki Aoki</dc:creator>
<dc:creator>Seiichi Watanabe</dc:creator>
<dc:creator>Shota Muraji</dc:creator>
<dc:creator>Takuro Kojima</dc:creator>
<dc:creator>Masao Yoshinaga</dc:creator>
<dc:creator>Seiko Ohno</dc:creator>
<dc:creator>Hiroshi Suzuki</dc:creator>
<dc:creator>Naokata Sumitomo</dc:creator>
<dc:creator>Yoshihisa Nakagawa</dc:creator>
<dc:creator>Koh Ono</dc:creator>
<dc:creator>Minoru Horie</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-specific clinical course of young patients with Brugada syndrome</dc:title>
<dc:identifier>pmid:39908976</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae739</dc:identifier>
</item>
<item>
<title>Sodium Reduction Legislation and Urinary Sodium and Blood Pressure in South Africa</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: In this cohort study, following South African regulations limiting sodium in 13 categories of processed foods, there was a significant reduction in 24HrNa excretion among this rural South African population, which was sustained with reductions in blood pressure consistent with levels of sodium excreted. These results support the potential health effects anticipated by effective implementation of population-based salt reformulation policies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5410. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Reductions in dietary salt are associated with blood pressure reductions; however, national governments that have passed laws to reduce sodium intake have not measured these laws' impact.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine if South African regulations restricting sodium content in processed foods were associated with reductions in sodium consumption and blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The HAALSI (Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa) study is a population-based cohort study among adults aged 40 years or older randomly selected from individuals living in rural Mpumalanga Province in South Africa. This study incorporated 3 waves of data (2014/2015, 2018/2019, and 2021/2022) from the HAALSI study to examine how 24-hour urine sodium (24HrNa) excretion changed among a population-based cohort following mandatory sodium regulations. Spot urine samples were collected across 3 waves, and data analysis was performed from 2023 to 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: South African regulations introduced in 2013 that reduced levels for the maximum amount of sodium in milligrams per 100 mg of food product by 25% to 80% across 13 processed food categories by 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: 24HrNa was estimated using the INTERSALT equation, and generalized estimating equations were used to assess changes in sodium excretion and blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 5059 adults 40 years or older, mean (SD) age was 62.43 years (13.01), and 2713 participants (53.6%) were female. Overall mean (SD) estimated 24HrNa excretion at baseline was 3.08 g (0.78). There was an overall reduction in mean 24HrNa excretion of 0.22 g (95% CI, -0.27 to -0.17; P &lt; .001) between the first 2 waves and a mean reduction of 0.23 g (95% CI, -0.28 to -0.18; P &lt; .001) between the first and third waves. The reductions were larger when analysis was restricted to those with samples in all 3 waves (-0.26 g for both waves 2 and 3 compared to wave 1). Every gram of sodium reduction was associated with a -1.30 mm Hg reduction (95% CI, 0.65-1.96; P = .00) in systolic blood pressure. The proportion of the study population that achieved ideal sodium consumption (&lt;2 g per day) increased from 7% to 17%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: In this cohort study, following South African regulations limiting sodium in 13 categories of processed foods, there was a significant reduction in 24HrNa excretion among this rural South African population, which was sustained with reductions in blood pressure consistent with levels of sodium excreted. These results support the potential health effects anticipated by effective implementation of population-based salt reformulation policies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908059</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5410>10.1001/jamacardio.2024.5410</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908059</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Thomas Gaziano</dc:creator>
<dc:creator>David Kapaon</dc:creator>
<dc:creator>Jacques D du Toit</dc:creator>
<dc:creator>Nigel J Crowther</dc:creator>
<dc:creator>Alisha N Wade</dc:creator>
<dc:creator>June Fabian</dc:creator>
<dc:creator>Carlos Riumallo-Herl</dc:creator>
<dc:creator>F Carla Roberts-Toler</dc:creator>
<dc:creator>Xavier Gómez-Olivé</dc:creator>
<dc:creator>Stephen Tollman</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sodium Reduction Legislation and Urinary Sodium and Blood Pressure in South Africa</dc:title>
<dc:identifier>pmid:39908059</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5410</dc:identifier>
</item>
<item>
<title>Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure-A Call to Action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Ten key points summarized workshop findings, with target cohorts for study proposed as a crucial next step. This workshop summary is intended as a call for action to address knowledge gaps and develop new strategies to improve outcomes in the large ambulatory population with C2D HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5328. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although these patients are commonly encountered in practice, national databases selectively capture the small groups accepted for heart transplant listing or left ventricular assist devices. The epidemiology, trajectories, and therapies for other ambulatory patients with advanced HF are poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: In December 2022, the National Heart, Lung and Blood Institute convened a team of experts to identify knowledge gaps and research priorities for the ambulatory population with limiting daily symptoms and transition toward refractory end-stage D HF, designated as stage C2D. This article summarizes the findings from that 3-day workshop. Workshop participants surveyed the initial challenges and knowledge gaps for (1) recognition of ambulatory C2D HF, (2) estimation of the magnitude of the affected population and identifiable subpopulations, and (3) physiologic phenotypes, such as low cardiac output, right HF, cardiorenal syndromes, congestive hepatopathy and frailty, which offer distinct targets for existing and emerging therapies. Social drivers of HF and patient preferences for quality/length of survival were highlighted as essential modifiers for personalization of therapies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Ten key points summarized workshop findings, with target cohorts for study proposed as a crucial next step. This workshop summary is intended as a call for action to address knowledge gaps and develop new strategies to improve outcomes in the large ambulatory population with C2D HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908057</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5328>10.1001/jamacardio.2024.5328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908057</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Shannon M Dunlay</dc:creator>
<dc:creator>Sean P Pinney</dc:creator>
<dc:creator>Anuradha Lala</dc:creator>
<dc:creator>Garrick C Stewart</dc:creator>
<dc:creator>Colleen McIlvennan</dc:creator>
<dc:creator>Renee P Wong</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Francis D Pagani</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>Rebecca Cogswell</dc:creator>
<dc:creator>Monica M Colvin</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:creator>Laura P Gelfman</dc:creator>
<dc:creator>Manreet K Kanwar</dc:creator>
<dc:creator>Michael S Kiernan</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Nader Moazami</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Joseph G Rogers</dc:creator>
<dc:creator>Kurt R Schumacher</dc:creator>
<dc:creator>Mark S Slaughter</dc:creator>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Jeffrey Teuteberg</dc:creator>
<dc:creator>Hannah A Valantine</dc:creator>
<dc:creator>Ersilia M DeFilippis</dc:creator>
<dc:creator>Debra D Dixon</dc:creator>
<dc:creator>Jessica R Golbus</dc:creator>
<dc:creator>Gaurav Gulati</dc:creator>
<dc:creator>Thomas C Hanff</dc:creator>
<dc:creator>Stephanie Hsiao</dc:creator>
<dc:creator>Sabra C Lewsey</dc:creator>
<dc:creator>Amanda D McCormick</dc:creator>
<dc:creator>Aditi Nayak</dc:creator>
<dc:creator>Kathleen N Fenton</dc:creator>
<dc:creator>Lisa Schwartz Longacre</dc:creator>
<dc:creator>Sujata M Shanbhag</dc:creator>
<dc:creator>Wendy C Taddei-Peters</dc:creator>
<dc:creator>Lynne Warner Stevenson</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure-A Call to Action</dc:title>
<dc:identifier>pmid:39908057</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5328</dc:identifier>
</item>
<item>
<title>Cardiovascular Hospitalizations Among Older Adults in the US and Denmark</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908055/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this international cross-sectional study, cardiovascular hospitalization rates were significantly higher in the US compared with Denmark. There were income-based differences in the burden of cardiovascular hospitalizations in both countries, although the magnitude of these disparities was much greater in the US.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5303. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease is the leading cause of death in the US. However, it remains unclear how the burden of cardiovascular events in the US compares with that of other high-income countries with distinct health care systems like Denmark, both overall and by income.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare cardiovascular hospitalization rates (acute myocardial infarction [MI], heart failure [HF], ischemic stroke) and associated outcomes among adults 65 years or older, overall and by income, between the US and Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This population-based cross-sectional study used national data from the US and Denmark from January 1, 2021, to January 1, 2022. The study population included all Medicare beneficiaries 65 years or older in the US and all adults 65 years or older in Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was age- and sex-standardized hospitalization rates for MI, HF, and ischemic stroke, as well as 30-day all-cause mortality rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The US study population included 58 614 110 adults 65 years or older (mean [SE] age, 74.6 [7.7] years; 32 179 146 female [54.9%]) of whom 1 171 058 (2.0%) were hospitalized for a cardiovascular event. The Danish study population included 1 176 542 adults 65 years or older (mean [SE] age, 75.3 [7.1] years; 634 217 female [53.9%]) of whom 16 305 (1.4%) were hospitalized with a cardiovascular event. The overall age- and sex-standardized cardiovascular hospitalization rate was significantly higher in the US compared with Denmark (risk ratio [RR], 1.50; 95% CI, 1.47-1.52), as were associated 30-day all-cause mortality rates (RR, 1.12; 95% CI, 1.06-1.17). Across conditions, the risk of hospitalization for MI (RR, 1.56; 95% CI, 1.51-1.61) and HF (RR, 2.37; 95% CI, 2.31-2.43) was significantly higher in the US compared with Denmark, whereas hospitalizations for ischemic stroke were lower (RR, 0.90; 95% CI, 0.88-0.93). Overall cardiovascular hospitalization rates in the US were more than 2-fold higher among low-income adults compared with higher-income adults (RR, 2.38; 95% CI, 2.25-2.47), whereas the magnitude of income-based disparities was smaller in Denmark (RR, 1.45; 95% CI, 1.39-1.50).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this international cross-sectional study, cardiovascular hospitalization rates were significantly higher in the US compared with Denmark. There were income-based differences in the burden of cardiovascular hospitalizations in both countries, although the magnitude of these disparities was much greater in the US.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908055</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5303>10.1001/jamacardio.2024.5303</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908055</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Frederikke Held Berg</dc:creator>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Gunnar H Gislason</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiovascular Hospitalizations Among Older Adults in the US and Denmark</dc:title>
<dc:identifier>pmid:39908055</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5303</dc:identifier>
</item>
<item>
<title>The Cardiovascular Disease Divide-A Tale of 2 High-Income Nations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5312. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908054</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5312>10.1001/jamacardio.2024.5312</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908054</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Cardiovascular Disease Divide-A Tale of 2 High-Income Nations</dc:title>
<dc:identifier>pmid:39908054</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5312</dc:identifier>
</item>
<item>
<title>Dietary Sodium- and Potassium-Enriched Salt Substitutes-The Tipping Point?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5430. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908031</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5430>10.1001/jamacardio.2024.5430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908031</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Daniel W Jones</dc:creator>
<dc:creator>Brent M Egan</dc:creator>
<dc:creator>Daniel Thomas Lackland</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dietary Sodium- and Potassium-Enriched Salt Substitutes-The Tipping Point?</dc:title>
<dc:identifier>pmid:39908031</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5430</dc:identifier>
</item>
<item>
<title>Error in the Author Affiliations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2025.0001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908030</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0001>10.1001/jamacardio.2025.0001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908030</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in the Author Affiliations</dc:title>
<dc:identifier>pmid:39908030</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0001</dc:identifier>
</item>
<item>
<title>Salt Substitution and Recurrent Stroke and Death: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39908026/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cluster trial demonstrate that salt substitution was safe, along with reduced risks of stroke recurrence and death, which underscores large health gains from scaling up this low-cost intervention among patients with stroke.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 5. doi: 10.1001/jamacardio.2024.5417. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The direct effect of consumption of salt substitutes on recurrent stroke and mortality among patients with stroke remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the effects of salt substitutes vs regular salt on the incidence of recurrent stroke and mortality among patients with stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Salt Substitute and Stroke Study (SSaSS), an open-label, cluster randomized clinical trial, was conducted in 600 northern Chinese villages (clusters). Patients who self-reported a hospital diagnosis of stroke were included in this prespecified subgroup analysis. Data were analyzed from November 2023 to August 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants were assigned to use either a salt substitute, consisting of 75% sodium chloride and 25% potassium chloride by mass, or regular salt.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After excluding 5746 persons without a baseline history of stroke, 15 249 patients with stroke (mean [SD] age, 64.1 [8.8] years; 6999 [45.9%] female; 8250 male [54.1%]) were included. Over a median (IQR) follow-up of 61.2 (60.9-61.6) months, the mean difference in systolic blood pressure was -2.05 mm Hg (95% CI, -3.03 to -1.08 mm Hg). A total of 2735 recurrent stroke events (691 fatal and 2044 nonfatal) and 3242 deaths were recorded. Recurrent stroke was significantly lower in the salt substitute vs regular salt group (rate ratio [RR], 0.86; 95% CI, 0.77-0.95; P = .005), with larger effects on hemorrhagic stroke (relative reduction, 30%; P = .002). Death rates were also significantly lower (RR, 0.88; 95% CI, 0.82-0.96; P = .003), with larger effects on stroke-related deaths (relative reduction 21%; P = .01). No significant difference was observed for hyperkalemia (RR, 1.01; 95% CI, 0.74-1.38; P = .96).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cluster trial demonstrate that salt substitution was safe, along with reduced risks of stroke recurrence and death, which underscores large health gains from scaling up this low-cost intervention among patients with stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02092090.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39908026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39908026</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5417>10.1001/jamacardio.2024.5417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39908026</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiong Ding</dc:creator>
<dc:creator>Xinyi Zhang</dc:creator>
<dc:creator>Liping Huang</dc:creator>
<dc:creator>Shangzhi Xiong</dc:creator>
<dc:creator>Zhifang Li</dc:creator>
<dc:creator>Yi Zhao</dc:creator>
<dc:creator>Bo Zhou</dc:creator>
<dc:creator>Xuejun Yin</dc:creator>
<dc:creator>Bingqing Xu</dc:creator>
<dc:creator>Yanfeng Wu</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>Maoyi Tian</dc:creator>
<dc:creator>Lijing L Yan</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Salt Substitution and Recurrent Stroke and Death: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39908026</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5417</dc:identifier>
</item>
<item>
<title>Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39907696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250206011539&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 5:ehae798. doi: 10.1093/eurheartj/ehae798. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39907696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250206011539&v=2.18.0.post9+e462414">39907696</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae798>10.1093/eurheartj/ehae798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39907696</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Samira Lakhal-Littleton</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?</dc:title>
<dc:identifier>pmid:39907696</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae798</dc:identifier>
</item>





























</channel>
</rss>